Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 6/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991518 | 0.88 | LMNA (0.65) | KMT2AMEN1LMNAAKR1C3SMN1; SMN2 | |
| SCHEMBL14597064 | 0.87 | KMT2A (0.61) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL5471844 | 0.85 | LMNA (0.71) | KMT2AMEN1LMNAAKR1C3SMN1; SMN2 | |
| SCHEMBL5467360 | 0.84 | LMNA (0.70) | KMT2AMEN1LMNAAKR1C3SMN1; SMN2 | |
| SCHEMBL2987927 | 0.84 | LMNA (0.60) | KMT2AMEN1LMNAAKR1C3SMN1; SMN2 | |
| SCHEMBL5461080 | 0.83 | LMNA (0.64) | KMT2AMEN1LMNAAKR1C3SMN1; SMN2 | |
| SCHEMBL5467482 | 0.83 | LMNA (0.66) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL5474219 | 0.83 | LMNA (0.76) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL5468998 | 0.83 | LMNA (0.68) | KMT2AMEN1LMNASMN1; SMN2MAPT | |
| SCHEMBL5472807 | 0.83 | LMNA (0.76) | KMT2AMEN1LMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | KMT2A 1132/4885MEN1 1223/4885LMNA 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.